The analysis of β3GNT9 expression in various tumors using the online database GEPIA revealed significant high β3GNT9 expression in esophageal cancer, glioblastoma, head and neck squamous cell carcinoma, low-grade glioma, pancreatic cancer, and thymic carcinoma (P<0.05), and significant low expression in chromophobe renal cell carcinoma, ovarian serous cystadenocarcinoma, prostate cancer, and endometrial cancer (P<0.05, Figure 9). Here, B3GNT9 is linked to central nervous system cancer.